Search clinical trials for: BGB-283

Total 2546 results

BeiGene

Completed

The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor

Solid Tumors

China
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

Solid Tumors

Australia, New Zealand
BeiGene
SpringWorks Therapeutics, Inc.

Recruiting

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Solid Tumor, Adult

Australia, United States
Nanjing Medical University
Beijing Anzhen Hospital; Second Affiliated Hospital of Nanchang University

Recruiting

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Thymosin α1) V

Acute Aortic Syndrome | Aortic Dissectio

China
BeiGene

Completed

BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

Healthy

Australia
Boehringer Ingelheim

Terminated

Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients

Cystic Fibrosis

United States
BeiGene

Terminated

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

Advanced Solid Tumors

Australia, Spain, New Zealand
BeiGene

Completed

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

Australia
BeiGene

Recruiting

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditions

China, Australia
BeiGene

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035

Autoimmune Diseases | Healthy Volunteers | Healthy Subjects | Healthy Participants | Healthy Adult Participants
BeiGene
Myriad Genetic Laboratories, Inc.

Completed

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Solid Tumors

United States, Spain, United Kingdom, France, Australia, New Zealand
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BerGenBio ASA

Terminated

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Brain and Central Nervous System Tumors

United States
BeiGene

Recruiting

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)

United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina
BeiGene

Active, not recruiting

Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

Mature B-cell Malignancies

China
BeiGene

Withdrawn

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Fudan University

Recruiting

Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy

Limited Stage Small Cell Lung Cancer

China
BeiGene

Recruiting

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma | Leukemia | Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Relapsed Chronic Lymphocytic Leukemia

China
BeiGene

Completed

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Locally Advanced or Metastatic Urothelial Bladder Cancer

Korea, Republic of, China
BeiGene

Completed

First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants

Not Determined

Australia, China
BeiGene

Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Cutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditions

China, Taiwan, Germany, France, Canada, Italy
BeiGene

Completed

A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China
BeiGene

Terminated

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)

United States, Australia, Puerto Rico, Spain
Australia New Zealand Gynaecological Oncology Group
BeiGene

Withdrawn

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE)

Ovarian Cancer | Carcinosarcoma
BeiGene

Recruiting

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Solid Tumor | Advanced Solid Tumor | Metastatic Solid Tumor

United States, Australia
BeiGene

Completed

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417

Healthy Volunteers

United States
BeiGene

Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

United States, New Zealand, Australia
BeiGene

Active, not recruiting

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Solid Tumor

Australia, United States
BeiGene

Recruiting

A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813

Advanced Solid Tumors

United States, Australia, Spain
BeiGene

Recruiting

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumor

China, United States, Australia, New Zealand, Korea, Republic of
BeiGene

Recruiting

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

China, Italy, Taiwan, Australia, Spain, Korea, Republic of, France, Thailand, United States, Georgia, Singapore, Canada
BeiGene

Recruiting

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2

Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
BeiGene

Withdrawn

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

Solid Tumors
BeiGene

Active, not recruiting

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Non Small Cell Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma (HNSCC) | Nasopharyngeal Carcinoma (NPC)

Canada, Australia, New Zealand, Korea, Republic of, United States, Malaysia, Thailand
BeiGene

Terminated

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China, Taiwan, Australia, United States
SpringWorks Therapeutics, Inc.

Recruiting

Mirdametinib + BGB-3245 in Advanced Solid Tumors

Advanced Solid Tumor

United States, Australia
MapKure, LLC

Recruiting

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Solid Tumor | B-Raf Mutation-Related Tumors

United States, Australia
BeiGene

Completed

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

Advanced Hepatocellular Carcinoma

China, Taiwan
BeiGene

Completed

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer

China, Korea, Republic of, United States
BeiGene

Active, not recruiting

Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer, Stage IV | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)

United States, China, Korea, Republic of, France, Spain, Australia, Austria
BeiGene

Completed

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Covid19

United States, Mexico, Brazil, South Africa
West China Hospital

Recruiting

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Thyroid Cancer

China
BeiGene

Completed

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

Advanced Cancer

United States, Taiwan, Australia, Korea, Republic of, New Zealand
Dong-A ST Co., Ltd.

Recruiting

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

Hepatitis B

Korea, Republic of
BeiGene

Recruiting

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Advanced Solid Tumor | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

Australia, China
Global Alliance for TB Drug Development

Completed

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Tuberculosis | Tuberculosis, Pulmonary

United States
BeiGene

Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Burton Tyrosine Kinase-Targeted Protein-Degrader

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Transformation | DLBCL Unclassifiable

China
Peter MacCallum Cancer Centre, Australia

Completed

MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial (MYPHISMO)

Adenoid Cystic Carcinoma | Colorectal Cancer

Australia
BeiGene

Completed

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

HER2-negative Breast Cancer

China
BeiGene

Completed

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

Covid19

Australia
BeiGene

Completed

AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

Korea, Republic of, Spain, China, Thailand, Taiwan, France

Search clinical trials for: BGB-283

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations